BTF's 2024 Updates on Hematology and Oncology, Fresno

Fresno, CA US
August 3, 2024

This CME-accredited oncology conference, BTF's 2024 Updates on Hematology and Oncology, Fresno, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

The expert faculty will present a comprehensive overview of recent updates in hematology and oncology. The program will feature in-depth discussions and analyses of the latest scientific discoveries and advancements. Faculty will contextualize these findings within clinical practice and explore their potential to alter current standards of care. This conference is designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, providing them with the latest updates in the field. Emphasizing a multidisciplinary approach, it will showcase the integration of new advancements into patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Sanjay Hinduja, MD - UCSF Fresno

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Course opens: 
05/06/2024
Course expires: 
10/03/2024
Event starts: 
08/03/2024 - 8:00am PDT
Event ends: 
08/03/2024 - 4:00pm PDT
Cost:
$350.00

August 3rd, 2024

All times are listed in Pacific Time (PT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:35 AM  Session 1 - Hematologic Malignancies

Session Chair: Haifaa Abdulhaq, MD

08:20 AM – 08:45 AM  MDS/Leukemias - Bart Scott, MD

08:45 AM – 09:10 AM  Multiple Myeloma - Alfred Chung, MD

09:10 AM – 09:35 AM  Lymphoma & CLL - Haifaa Abdulhaq, MD


09:35 AM – 10:05 AM  Break & Exhibits


10:05 AM – 10:55 AM  Session 2 - Thoracic Oncology

Session Chairs: Andy (Sew-Chung) Jang, MD & Ranjan Pathak, MD

10:05 AM – 10:30 AM  Early-Stage Lung Cancer - Matthew Gubens, MD, MS, FASCO

10:30 AM – 10:55 AM  Advanced Lung Cancer - Shiruyeh Schokrpur, MD, PhD


10:55 AM – 12:10 PM  Session 3 - Case-Based Presentations

Session Chair: Sanjay Hinduja, MD

10:55 AM – 11:10 AM  Case 1: Sarcoma - Varun Monga, MBBS

11:10 AM – 11:25 AM  Case 2: Brain Tumor Updates - Jerome Graber, MD, MPH

11:25 AM – 11:40 AM  Case 3: Head and Neck Cancer - Hyunseok Kang, MD, MPH, FACP

11:40 AM – 11:55 AM  Case 4: Lung Cancer - Deepti Behl, MD

11:55 AM – 12:10 PM  Q and A


12:10 PM – 01:10 PM  Lunch & Exhibits


01:10 PM – 02:00 PM  Session 4 - Genitourinary Cancer

Session Chair: Jude Khatib, MD

01:10 PM – 01:35 PM  Kidney and Prostate Cancer - Jude Khatib, MD

01:35 PM – 02:00 PM  Bladder Cancer - Mamta Parikh, MD, MS


02:00 PM – 02:50 PM  Session 5 - GI Cancer

Session Chair: Jun Gong, MD

02:00 PM – 02:25 PM  Upper GI Malignancies - Geoffrey Buckle, MD, MPH

02:25 PM – 02:50 PM  Lower GI Malignancies - Jun Gong, MD 


02:50 PM – 03:20 PM  Break & Exhibits


03:20 PM – 04:10 PM  Session 6 - Breast Cancer

Session Chair: Li Lisa Ge, MD

03:20 PM – 03:45 PM  Non-Metastatic Breast Cancer - Shipra Gandhi, MD

03:45 PM – 04:10 PM  Metastatic Breast Cancer - Mark Pegram, MD


04:10 PM  Adjourn

DoubleTree by Hilton Hotel Fresno Convention Center
2233 Ventura St
Fresno, CA 93721
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Sanjay Hinduja

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Kite;.

Alfred Chung, Assistant Professor

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Financial Support) with Caelum Biosciences;.
has a financial relationship (Travel) with Janssen;.
has a financial relationship (Financial Support) with Carsgen;.
has a financial relationship (Financial Support) with Bristol Myers Squibb;.
has a financial relationship (Financial Support) with Abbvie;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Janssen;.
has a financial relationship (Financial Support) with Cellectis;.

Li Ge, MD

has no relevant financial relationships to disclose at this time.

Jun Gong, MD

has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Elsevier;.
has a financial relationship (Professional Services) with Seagen;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Eisai;.

Andy Jang, Assistant Professor of Medicine

has no relevant financial relationships to disclose at this time.

Jude Khatib, MD

has no relevant financial relationships to disclose at this time.

Ranjan Pathak, MBBS, MHS, FACP

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno

has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Novartis;.

Geoffrey Buckle, MD, MPH

has a financial relationship (Independent contractor) with IDR;.
has a financial relationship (Independent contractor) with Capvision;.
has a financial relationship (Independent contractor) with Atheneum;.
has a financial relationship (Independent contractor) with VMLY&R;.
has a financial relationship (Independent contractor) with Tech.spert;.
has a financial relationship (Independent contractor) with Guidepoint;.
has a financial relationship (Independent contractor) with Alpha Insights;.

Shipra Gandhi, MD, MS

has a financial relationship (Other) with Biotheranostics ;.
has a financial relationship (Other) with Astrazeneca;.

Jun Gong, MD

has a financial relationship (Professional Services) with Elsevier;.
has a financial relationship (Professional Services) with Seagen;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Bayer;.

Matthew Gubens

has a financial relationship (Independent contractor) with Merus;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Guardant;.
has a financial relationship (Independent contractor) with Atreca;.
has a financial relationship (Independent contractor) with Johnson and Johnson;.
has a financial relationship (Independent contractor) with Genzyme;.
has a financial relationship (Independent contractor) with AnHeart;.
has a financial relationship (Independent contractor) with Invitae;.
has a financial relationship (Independent contractor) with Cardinal Health;.
has a financial relationship (Independent contractor) with Surface;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Gilead;.

Jude Khatib, MD

has no relevant financial relationships to disclose at this time.

Mamta Parikh, MD,MS

has a financial relationship (Other) with Sanofi Aventis;.
has a financial relationship (Other) with Bristol Myers Squibb;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Karyopharm;.

Mark Pegram, MD

has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novartis;.

Shiruyeh Schokrpur, M.D., Ph.D.

has no relevant financial relationships to disclose at this time.

Bart Scott, MD

has a financial relationship (Professional Services) with Alexion;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Morphosys;.
Case Presenter(s)

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with janssen;.
has a financial relationship (Professional Services) with BMS;.

Jerome Graber, MD, MPH, FAAN

has a financial relationship (Independent contractor) with Servier;.
has a financial relationship (Independent contractor) with M3;.

Hyunseok Kang, MD, MPH

has a financial relationship (Independent contractor) with Remix Therapeutics;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Bertis ;.
has a financial relationship (Independent contractor) with Coherus Biosciences;.
has a financial relationship (Independent contractor) with Pin Therapeutics;.
has a financial relationship (Independent contractor) with Cue Bio;.
has a financial relationship (Independent contractor) with LG Chem;.

Varun Monga

has a financial relationship (Grant Or Contract) with Cogent Biosciences ;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Oblato Therapeutics;.
has a financial relationship (Grant Or Contract) with Orbus Therapetuics ;.
has a financial relationship (Grant Or Contract) with Prelude Therapeutics;.

Available Credit

  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Amgen OncologyGeneral ExhibitDiane Leese
ApellisGeneral ExhibitKathryn Larocca
AstraZenecaGeneral ExhibitArmando Pina
Boehringer Ingelheim Pharmaceuticals, Inc.General ExhibitTodd Valdez
Daiichi SankyoGeneral ExhibitBrandon Chors
DSI 2nd TableGeneral ExhibitGrant Garcia
Eisai OncologyGeneral ExhibitBrian Good
Geron CorporationGeneral ExhibitBrina Wright
GileadGeneral ExhibitOlivia Lazaro-Delacerda
IncyteGeneral ExhibitJason Roos
IpsenGeneral ExhibitLindsay Alistar
MerckGeneral ExhibitWendy Leal
SanofiGeneral ExhibitCollin Dumas
TakedaGeneral ExhibitNatalie Sweeney
   
   
   

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.